Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol
| العنوان: | Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol |
|---|---|
| المؤلفون: | Ulaner, Gary A, Mankoff, David A, Clark, Amy S, Fowler, Amy M, Linden, Hannah M, Peterson, Lanell M, Dehdashti, Farrokh, Kurland, Brenda F, Mortimer, Joanne, Mouabbi, Jason, Moon, Dae Hyuk, de Vries, Elisabeth G E |
| المساهمون: | Guided Treatment in Optimal Selected Cancer Patients (GUTS) |
| المصدر: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 64(3), 351-354. SOC NUCLEAR MEDICINE INC |
| بيانات النشر: | SOC NUCLEAR MEDICINE INC, 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Breast Neoplasms/diagnostic imaging, Estradiol/metabolism, Receptors, Estrogen, Biopsy, Positron-Emission Tomography, Receptors, Humans, Radiology, Nuclear Medicine and imaging, Female, Estrogen, United States, Molecular Imaging |
| الوصف: | PET imaging with 16α- 18F-fluoro-17β-fluoroestradiol ( 18F-FES), a radiolabeled form of estradiol, allows whole-body, noninvasive evaluation of estrogen receptor (ER). 18F-FES is approved by the U.S. Food and Drug Administration as a diagnostic agent "for the detection of ER-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer." The Society of Nuclear Medicine and Molecular Imaging (SNMMI) convened an expert work group to comprehensively review the published literature for 18F-FES PET in patients with ER-positive breast cancer and to establish appropriate use criteria (AUC). The findings and discussions of the SNMMI 18F-FES work group, including example clinical scenarios, were published in full in 2022 and are available at https://www.snmmi.org/aucTest Of the clinical scenarios evaluated, the work group concluded that the most appropriate uses of 18F-FES PET are to assess ER functionality when endocrine therapy is considered either at initial diagnosis of metastatic breast cancer or after progression of disease on endocrine therapy, the ER status of lesions that are difficult or dangerous to biopsy, and the ER status of lesions when other tests are inconclusive. These AUC are intended to enable appropriate clinical use of 18F-FES PET, more efficient approval of FES use by payers, and promotion of investigation into areas requiring further research. This summary includes the rationale, methodology, and main findings of the work group and refers the reader to the complete AUC document. |
| اللغة: | English |
| تدمد: | 1535-5667 0161-5505 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5a1a1e009eb7f8a5d7052d04a8c4206Test https://research.rug.nl/en/publications/d03f8eff-aeaa-47b2-b78c-737bfa6d2e1eTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b5a1a1e009eb7f8a5d7052d04a8c4206 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15355667 01615505 |
|---|